Archive for 2010

Drug Patent Expirations in September 2010

Drug Patent Expirations in September 2010 *Drugs may be covered by multiple patents Tradename Applicant Generic Name Patent Number Patent Expiration MUSE Vivus alprostadil 5,242,391 Sep 7, 2010 ADVAIR DISKUS 100/50 Glaxosmithkline fluticasone propionate; salmeterol xinafoate RE40045 Sep 7, 2010 ADVAIR DISKUS 500/50 Glaxosmithkline fluticasone propionate; salmeterol xinafoate RE40045 Sep 7, 2010 ZINECARD Pharmacia And […]


Orphan Drug Report

I’ve posted a new Orphan Drug Report at thinkPharm.com. This new report complements the Drug Patent Inventor Report, and profiles pharmaceutical drugs with FDA Orphan Drug Exclusivity. The Orphan Drug Report includes: The tradename, applicant, ingredient, and Orphan exclusivity expiration dates for each Orphan Drug Details on each NDA and product number, including Dosage, Strength, […]


Bio Bank Helps Lethal Brain Cancer Patient Maintain Tissue Ownership Defy the Odds

HealthBank empowering patients with full ownership and control of their stored tumor tissue integral for tailored treatment courses; Six-year brain tumor survivor Bob Gibbs exemplifies the importance of banking tumor tissue for personalized cancer vaccines, which saved his own life Here’s something to wrap your brain around: tumors saves lives!  Few cancer patients realize that […]


Coming soon – Biotechnology Entrepreneurship: From Science to Solutions

Coming soon, a book by Michael L. Salgaller, PhD. In this new book — Biotechnology Entrepreneurship: From Science to Solutions — Michael combines the voices of a diverse set of industry insiders with extensive experience in biotechnology commercialization to prepares nascent founders, managers, investors, and other biotechnology company stakeholders to position themselves and their companies […]


Synthetic Biology: Revolutionary or Evolutionary

Synthetic biology has been hailed as a revolution in biotechnology, enabling bold new possibilities in areas such as energy production, medicines, and other applications. But, is it really revolutionary, or just a new tool? With our current knowledge of the structure and function of proteins, the ability for de novo engineering is relatively limited. The […]